Background. The prevalence, risk factors, and potential hormonal abnormalities associated with gynecomastia in a cohort of HIV-infected men are poorly understood.
does not distinguish between glandular and fat tissue [1] . Breast enlargement, particularly among women, has been commonly reported among the body fat changes that have been included in the clinical diagnosis of lipodystrophy since the time of the initial recognition of the condition among HIV-infected patients [3, 4] . In contrast, gynecomastia has been less commonly identified among HIV-infected men, and studies involving this population usually have been limited to small case series in which hormonal studies either were lacking or were scarce [5] [6] [7] [8] [9] [10] [11] [12] .
We performed a study in Barcelona, Spain, that was specifically designed to determine the prevalence, risk factors, and potential hormonal abnormalities associ-ated with gynecomastia in a large cohort of HIV-infected men who were followed at 2 referral centers in which 175% of the patients were men.
PATIENTS AND METHODS

Patients.
Clinically stable, HIV-infected adult men from 2 referral HIV centers in Barcelona were specifically evaluated to detect breast enlargement during their first regular clinical visits within the period occurring from January through July 2003. Each participating patient was asked to remove the clothes from the upper part of his body. Breast enlargement was detected visually and was confirmed by palpation. Exploration was performed, after specific training, by the doctor in charge of each patient. If breast enlargement was detected, sonography was subsequently performed to confirm gynecomastia [13] . Patients with sonographically proven gynecomastia were considered to be case patients. For each case patient with breast enlargement, a randomly selected male patient without breast enlargement was chosen as a control subject for the present study. Computerized random selection was performed to recruit control subjects among patients without clinically evident breast enlargement. The institutional ethics committee at each center approved the study, and every patient gave written, informed consent before entry into the present study.
Assessments. For each case patient and control subject, we collected clinical data, including age, body mass index, and clinical diagnosis of lipodystrophy (as described elsewhere [14] ), as well as prior diagnosis of symptomatic hyperlactatemia, current antiretroviral therapy and duration of exposure to each antiretroviral drug [1] [2] , history of injection drug use, and serological status regarding hepatitis B and hepatitis C. In addition, laboratory parameters, including plasma HIV-1 RNA load, CD4 cell counts, free testosterone index (normal range, 50%-140%), and levels of fasting triglycerides (normal range, 50-150 mg/dL), total cholesterol (normal range, 148-247 mg/ dL), total testosterone (normal range, 300-1200 ng/dL), sex hormone-binding globulin (normal range, 9-66 mmol/L), 17-b-estradiol (normal range, 10-50 pg/mL), follicle-stimulating hormone (FSH; normal range, 1-10 U/L), luteinizing hormone (LH; normal range, 1-10 U/L), prolactin (normal range, 0-20 ng/mL), thyroid-stimulating hormone (TSH; normal range, 0.4-4 mIU/L), and cortisol (normal range, 4-19 mg/dL), were also measured, using the same laboratory procedures, at each participating center.
The number of CD4 T lymphocyte cells was measured by flow cytometry. Plasma HIV-1 RNA loads were measured by PCR assay (Amplicor HIV Monitor; Roche Diagnostic Systems; lower limit of detection, 200 copies/mL). Levels of total cholesterol and triglycerides were determined using enzymatic reagents (Trinder; Bayer Diagnostics) adapted to a Cobas Mira automated analyzer (Hoffmann-LaRoche). Serum LH, FSH, and prolactin levels were measured using an immunoenzymatic assay with 2 monoclonal antibodies (Technicon Immuno-1 system; Bayer Diagnostics). Levels of estradiol and testosterone were measured using a competitive immunoenzymatic assay with the Technicon Immuno-1 system. The coefficient of variation was !5% for both techniques. Levels of sex hormonebinding globulin were determined using a chemiluminiscent method with 2 monoclonal antibodies (Immulite 2000; DPC). The coefficient of variation was !6%. TSH levels were determined by a direct chemiluminiscent immunoassay that uses 2 specific antibodies (ACS Centaur; Bayer); one of the antibodies is monoclonal, and the other is polyclonal. The interassay coefficient of variation for values in the normal range was !4%.
Definitions. "Gynecomastia" was defined by echogenicity suggesting glandular tissue on an ultrasonogram [13] . Sonography was performed with a 9-MHz linear array transducer by the same operator at each participating center.
Clinical assessment and physical examination to detect body fat abnormalities consistent with lipodystrophy were performed as described elsewhere [14] . The extent of body fat abnormalities was reported by the physician as being moderate or severe if the abnormalities were clinically evident at examination. For the purpose of analysis, body fat abnormalities were categorized as lipoatrophy or lipoaccumulation, as described elsewhere [14] . No objective measurements of body composition were performed.
Hypogonadism was defined by a low free-testosterone index; hypogonadism was considered to be primary, if LH levels were high, or secondary, if LH levels were normal or low [1, 2] . The free testosterone index was considered to be the proportion of testosterone that does not bind to sex hormone-binding globulin and, therefore, remains free in plasma to be metabolically active. Hypothyroidism was defined by a higher-than-normal TSH level [2] .
Statistical analysis. Statistical analysis was performed with the use of Stata software, version 7.0 (Stata). Comparisons between case patients and control subjects were performed using the x 2 test or Fisher's exact test. The factors associated with gynecomastia were investigated using multivariate logistic regression analyses. Significant variables in the univariate analysis were chosen to be entered into the multivariate models. Simple comparisons were made with the use of a 2-sided a level of 0.05.
RESULTS
Prevalence of gynecomastia.
From January through July 2003, a total of 2275 adult HIV-infected men were assessed for the presence of breast enlargement during routine clinical visits. Forty-four patients had clinically evident breast enlargement at ) was significantly P p .03 higher among case patients than among control subjects. The rest of the clinical factors were more similar among both case patients and control subjects. Table 2 shows the antiretroviral drugs used by case patients and control subjects at the time of the present study. Significant differences were found between case patients and control subjects regarding the proportions of patients who were receiving zidovudine, stavudine, and/or efavirenz. The proportion of patients who were receiving zidovudine was higher among the control subjects than among the case patients (15 ), but no other variables were found 23.4 ‫ע‬ 3.2 P p .05 to be associated with hypogonadism. No significant differences were detected between case patients and control subjects with regard to the levels of most of the hormones measured, with the exception of the free testosterone index and TSH levels (table 4). The mean free testosterone index (‫ע‬SD) was significantly lower among case patients than among control subjects ( vs. 42.6% ‫ע‬ 24.0% ;
). Furthermore, the proportion of 58.1% ‫ע‬ 25.3% P p .006 patients with hypogonadism was significantly higher among case patients than among control subjects (27 [67.5%] of 40 patients vs. 17 [38.6%] of 44 patients;
). The pro-P p .008 portion of patients with high levels of sex hormone-binding globulin was also significantly higher among case patients than among control subjects (14 [35%] of 40 patients vs. 6 [13.6%] of 44 patients;
). Mean TSH levels (‫ע‬SD) were sig-P p .02 nificantly higher among case patients than among control subjects ( mIU/L vs. mIU/L; ); how-2.5 ‫ע‬ 1.4
1.3 ‫ע‬ 0.9 P p .0001 ever, the proportion of patients with hypothyroidism among case patients (4 [10.0%] of 40 patients) was not significantly different than the proportion among control subjects (1 [2.3%] of 44 patients) (
). Among case patients, patients with P p .3 hypogonadism and patients without hypogonadism differed clinically only by age. Case patients with hypogonadism ( ) were older (mean age ‫ע‬ SD, years) than n p 27 46 ‫ע‬ 9 patients without hypogonadism ( ; mean age ‫ע‬ SD, n p 13 years) ( ). Secondary hypogonadism was more 38 ‫ע‬ 8 P p .01 common than primary hypogonadism among both case patients and control subjects. Among the 27 case patients with hypogonadism, it was primary in 6 (22%) and secondary in 21 (78%); among the 17 control subjects with hypogonadism, it was primary in 2 (12%) and secondary in 15 (88%).
When hypogonadism was included as a variable in the multivariate logistic regression model, along with the variables of chronic hepatitis C, lipoatrophy, current stavudine therapy, and current efavirenz therapy, the following variables emerged as independent factors associated with gynecomastia: hypogonadism (adjusted OR, 7.6; 95% CI, 1.8-32.2;
), chronic P p .003 hepatitis C (adjusted OR, 6.1; 95% CI, 1.8-20.6; ), P p .003 and lipoatrophy (adjusted OR, 5.6; 95% CI, 1.7-18.6; P p ). .005
DISCUSSION
We found that 1.8% of the HIV-infected men in our cohort had gynecomastia. Several cohort studies with differences in the design of the study and in the definition of gynecomastia have reported incidences of 0.8-2.4 cases/100 patient-years and prevalences of 2.8%-5.1% [15] [16] [17] [18] .
The pathogenesis of and the risk factors for gynecomastia among HIV-infected men remain poorly understood. In several studies [7, 19, 20] , associations between gynecomastia and current therapy with specific antiretroviral drugs, including sta- vudine [5, 6, 11] and efavirenz [8, 21] , have been reported. However, these studies did not take into account the duration of exposure to individual antiretroviral agents; it would be reasonable to consider whether gynecomastia was an antiretroviral-related long-term adverse effect [14] . The fact that no association with the duration of exposure to any antiretroviral agent has been found argues against gynecomastia as an adverse effect associated with any specific antiretroviral drug or family.
In the present study, current therapy with stavudine and/or efavirenz was significantly associated with gynecomastia, although the total duration of exposure to these specific antiretrovirals was not. We found that lipoatrophy and chonic hepatitis C were independently associated with gynecomastia. Gynecomastia was initially considered to be part of the lipodystrophy syndrome, but breast enlargement was more commonly reported in association with lipohypertrophy than with lipoatrophy [3, 4] . Although the association between chronic hepatitis C and gynecomastia could be explained by the degree of underlying liver insufficiency, none of our patients had end-stage liver disease. Whichever pathogenic mechanism may be involved, ultimately, in lipoatrophy and chronic hepatitis C, the risk carried by these variables was independent of hypogonadism.
A few published reports that have included hormonal studies had severe limitations, including lack of reporting of specific hormonal values [16, 18] , lack of measurement of free testosterone [8] , or lack of hormonal measurements for all of the patients included in the studies, because of the retrospective designs of the studies [21] . In the general population, derangements in levels of sexual hormones, such as a decreased ratio of free androgens to free estrogens and/or an increased sensitivity of the breast to normal circulating estrogens, have been associated with gynecomastia [1] . We found that hypogonadism was more prevalent among patients with gynecomastia than among patients without gynecomastia and that hypogonadism was identified as an independent factor for gynecomastia. Although conditions defined by abnormal levels of sexual hormones-in particular, hypogonadism-have been reported among HIV-infected men [22] , we are unaware of studies that associate hypogonadism with gynecomastia among HIVinfected men. Surprisingly, we found that hypogonadism was not unusual among control subjects, in contrast to the findings of other studies that have been performed during the HAART era [23, 24] , and we believe that this finding deserves to be analyzed in other cohorts and deserves additional investigation in future studies. Hypogonadism was more frequently secondary than primary, a result similar to that of other reports on hypogonadism among HIV-infected men who were receiving HAART [22] , although the ultimate explanation of this finding cannot be obtained from the present study.
Although the management and outcome of gynecomastia were not objectives of the present study, we feel that it is worthwhile to mention that gynecomastia improved or reverted in a substantial proportion of patients, without any specific intervention. For the patients with persistent gynecomastia, testosterone was shown to be effective and safe when administered either transdermally or intramuscularly for several weeks or months.
In summary, gynecomastia among HIV-infected men is an uncommon condition with a prevalence similar to that reported in the general male population. In contrast, hypogonadism among HIV-infected adult men seems to be a condition that has been underestimated in frequency, and it was an independent factor associated with gynecomastia. Lipoatrophy and chonic hepatitis C virus infection were also identified as independent factors associated with gynecomastia.
